On Jan. 08, Mellett Paul J divested U.S. $273,463 in shares of Enanta Pharmaceuticals Inc.. The Treasurer, CFO sold 6,000 shares at a price per share of $45.58. The transaction decreased this specific insider’s holdings to 61,759 shares worth around $2.82 million at present.
Evercore ISI launched its Enanta Pharmaceuticals Inc. [ENTA] rating to the equivalent of an Underperform and assigned the price target of $30, in a research note dated November 24, 2020. That figure represents around a -52.03% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with Evercore ISI’s analysts assigning the shares to “an Underperform” rating in a research note to investors issued in late November. In addition, there was a new coverage from Piper Sandler on August 26, 2020. The research firm rated ENTA “an Overweight”.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Is Enanta Pharmaceuticals Inc. [NASDAQ:ENTA] a Good Buy Right Now?
It should be noted that ENTA technical indicators for short, intermediate as well as long term progress have placed an overall average of 40% as Sell. The average signal changed from 100% Sell in the last week and compares with 100% Sell in the past month. Data from Enanta Pharmaceuticals Inc.’s Trend Spotter indicated that the signals were Strongest. The stock current average is 0.17 million shares in the past 20 days and the short term average signal indicates a 50% Sell. In the last 50 days, the average trading volume was 0.16 million shares while the medium term average advocated for 50% Sell. The average long-term signal stands at 50% Sell and the 100-day average volume stands at 0.17 million shares.
ENTA Price Performance
On Wall Street, Enanta Pharmaceuticals Inc. [NASDAQ:ENTA] finished Friday’s session down -0.44% at $45.61. The stock went up to $46.87 at the same session while its lowest single day price was $44.6201. In the last five days, it saw a rise of about 8.34%, Enanta Pharmaceuticals Inc. shares gained by almost 8.34% since the beginning of the year. However, the share price has dropped to as low as -25.49% below its one year high. On 01/08/21, the company shares recorded $46.87, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/05/21, the same year at $40.87. The company’s shares have declined by -24.40% in the past year. The 50-day SMA achieved is $43.57 while the 200-day SMA is $47.97. Volume dropped to 0.15 million from 0.2 million in the previous session.
ENTA Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 44.53 level, and in case of violation of this particular level, it will cause more drop to 43.45 level. On the upper level, 47.95 is still the key resistance. The stock may increase to the subsequent resistance at 46.78. The Relative Strength Index (RSI) pinned on the 14-day chart is 63.06, implying a neutral technical stance while the MACD stands at 2.03, meaning price will increase in the next trading period. Percent R indicator moved to 19.24%, implying bullish price movement. Stochastic %K at 87.77% suggest selling the stock.
What is the short interest in Enanta Pharmaceuticals Inc.?
Short interest in the Enanta Pharmaceuticals Inc. stock has surged, increasing by 0.14 million shares to total 2.29 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 2.43 million, data from Yahoo Finance shows. The decrease of -6.11% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 13.93% of the overall float for the stock.
Enanta Pharmaceuticals Inc.’s Biggest Shareholders: Who Owns Enanta Pharmaceuticals Inc. [ENTA]?
Filings by BlackRock Fund Advisors showed that the firm now holds a total of 2,847,790 shares or roughly 14.18% of the outstanding ENTA shares. This means their shares have increased by 151,162 from the 2,847,790 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, Farallon Capital Management LLC updated stake is worth $73,130,000. Details in the latest 13F filings reveal that The Vanguard Group, Inc. acquired their 1.85% stake valued at $69,574,522 while Renaissance Technologies LLC added theirs at $42,394,800. During the last quarter, The Vanguard Group, Inc. raised 30,632 of its shares in Enanta Pharmaceuticals Inc. while Renaissance Technologies LLC bought 86,100 shares. The T. Rowe Price Associates, Inc.’s holdings currently number 974,429 shares at $44443706.69. According to the firm’s last 13F report, SSgA Funds Management, Inc. shares in the company at filing stood at 963,518 shares, roughly $39,696,942.
ENTA Earnings Forecast For The Current Quarter
Enanta Pharmaceuticals Inc. [ENTA] is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $27.23M and an earnings per share of -$0.79 for Dec 2020. Looking further ahead, the company is expected to report revenue of $21.54M at an EPS of -$1.12 for Mar 2021. The estimates represent -8.30% and -41.00% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
ENTA Earnings Estimates For The Current Year
For the financial year, Enanta Pharmaceuticals Inc. [NASDAQ:ENTA] is expected to bring in revenue of $99.25M. The returns are nearly $-23.22 million lower than the company’s actual revenue recorded in the fiscal year 2020. In terms of EPS for the 2021, estimate put it at -4.04, lower than that of FY20 by -$2.23. Estimates put this year’s earnings growth at -123.20%, -41.30% for the next. As for sales, forecasts are for a decrease of -19.00% in the current fiscal year and a further -8.30% over the following year.
What are analyst thoughts on Enanta Pharmaceuticals Inc.?
Looking forward to the Enanta Pharmaceuticals Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Enanta Pharmaceuticals Inc. stock at $55.00 within the next 12 months, which represents almost 17.07 per cent growth from its previous closing price of $45.61. The highest analysts’ target for Enanta Pharmaceuticals Inc. stock projections is $107.00 and the lowest one is $30.00. Still, 8 analysts sharing their consensus rating for ENTA stock in 2021 agree that it is a Hold.